AFFiRiS raises €10M; FDA clears IND applications for BiondVax flu vax and Genticel HPV jab;

> AFFiRiS raised €10 million in a financing round. The funding will be used to advance its AFFITOME technology for the prevention and therapy of chronic illnesses, including Parkinson's disease. Release

> BiondVax ($BVXV) announced that its Investigational New Drug Application for its universal flu vaccine candidate was accepted by the FDA. News

> Genticel announced that the FDA has cleared its IND to conduct a Phase I study of its HPV candidate. Release

> France-based Biosantech announced that its HIV vaccine candidate is safe and not toxic for patients. The results are based on a study involving 48 HIV-positive patients. More

> The American Medical Association seeks to put an end to exemptions to immunizations that are not for medical reasons. Story

> The Defense Threat Reduction Agency is investing $5.2 million in EpiVax for the development of a new vaccine against Q fever. Release

Suggested Articles

Having struck two COVID-19 vaccine supply deals already, EU officials are in discussions with Novavax, as well.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.